A new clinical trial involving oxytocin was registered as of October 2, 2026. The study, titled "Effect of Intravenous Oxytocin on Post Dural Puncture Headache After Caesarean Sections," is listed under identifier NCT07853924.
The trial is designated Phase 4 and is currently listed with a status of not yet recruiting. According to the registration, the study will examine intravenous oxytocin administration in the context of post dural puncture headache occurring after caesarean sections.
No participants have been enrolled yet given the not yet recruiting status. No outcomes, efficacy data, or safety findings have been reported as part of this registration. The listing reflects only the planned design and scope of the study at this stage.
Oxytocin remains an approved compound, and this Phase 4 trial represents further investigation within its approved use context. Updates to recruitment status or results would be expected as the trial progresses through subsequent stages.
Readers interested in background on this compound can consult the oxytocin overview for additional context.